Sponsor Overview
Explore verified public information about Celcuity Inc's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Celcuity’s Expanded Access Program is only being offered to patients who initially received our investigational medicine as a participant in a clinical trial that is no longer open. Participation in our Expanded Access Program will end once the investigational medicine is approved and becomes commercially available in the patient’s country.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Breast Neoplasm Malignant Female
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.